A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results Simply Wall St 09:23 Wed, 27 May
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid FiercePharma 16:06 Thu, 21 May
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data Scrip Pharma Intelligence 15:45 Thu, 21 May
BioMarin Announces Positive Phase 3 Pivotal Study Results for Voxzogo® (vosoritide) in Children with Hypochondroplasia PR Newswire (Press Release) 21:22 Wed, 20 May
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint Clinical Trials Arena 10:39 Wed, 20 May
BioMarin’s BMN 401 Fails To Impress In Phase III ENPP1 Deficiency Study Scrip Pharma Intelligence 15:52 Tue, 19 May
Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness Simply Wall St 11:05 Tue, 19 May
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency PR Newswire (Press Release) 14:06 Mon, 18 May
